In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …

Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …

Gastric cancer is one of the most aggressive malignancies, with limited treatment options in
both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

Abstract Purpose: Even if RAS-BRAF wild-type and HER2/MET–negative metastatic
colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired …

Background While the negative prognostic role of BRAF V600E mutation in metastatic
colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 …

The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood,
urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor …

Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …

The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …

In the last two decades, great efforts have been made in the treatment of metastatic
colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs …